Sequential chemotherapy using gemcitabine+carboplatin followed by gemcitabine+carboplatin+docetaxel for advanced upper-tract urothelial cancer
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605490775 | ||
| 003 | CHVBK | ||
| 005 | 20210128100506.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20151201xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10147-015-0846-z |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10147-015-0846-z | ||
| 245 | 0 | 0 | |a Sequential chemotherapy using gemcitabine+carboplatin followed by gemcitabine+carboplatin+docetaxel for advanced upper-tract urothelial cancer |h [Elektronische Daten] |c [Takahiro Yoneyama, Atsushi Imai, Shingo Hatakeyama, Yasuhiro Hashimoto, Takuya Koie, Chikara Ohyama] |
| 520 | 3 | |a Background: Retrospective evaluation of the effectiveness and adverse events (AEs) of a sequential chemotherapy regimen using gemcitabine+carboplatin (GCarbo) followed by GCarbo+docetaxel (GCarboD) for advanced upper-tract urothelial carcinoma (UTUC). Methods: We treated 56 patients with advanced UTUC. Mean patient age was 68.9years, creatinine clearance was 51.2mL/min, and the observation period was 20months. Patients received two courses of GCarbo comprising 800mg/m2 gemcitabine on days 1, 8, and 15, and carboplatin at an area under the curve of four on day 2. If this regimen was effective, we administered two more courses of GCarbo; if the regimen was ineffective, we switched to two courses of GCarboD (70mg/m2). Results: Complete (n=3) and partial response (PR; n=25) were achieved after GCarbo. Mean response duration was 9.7months. Two of 17 cases achieved PR after GCarboD treatment (mean duration, 31.5months). Median survival was 14.0months with the GCarbo/GCarboD regimen. Responders to GCarbo therapy survived significantly longer. AEs with the GCarbo regimen included 31 instances of G3/4 blood toxicity and 8 instances of G3/4 urticaria; however, there were only 6 instances of G3/4 gastrointestinal complications. AEs with the GCarboD regimen included 16 instances of blood toxicity and 8 instances of gastrointestinal complications. Neither regimen resulted in G3/4 renal toxicity. Conclusions: GCarbo and GCarboD chemotherapy may be administered safely to patients with advanced UTUC, with or without renal dysfunction. Response to GCarbo was high (50.0%) whereas GCarboD was of limited effectiveness for non-responders to GCarbo. | |
| 540 | |a Japan Society of Clinical Oncology, 2015 | ||
| 690 | 7 | |a Upper-urinary tract |2 nationallicence | |
| 690 | 7 | |a Urothelial carcinoma |2 nationallicence | |
| 690 | 7 | |a Carboplatin |2 nationallicence | |
| 690 | 7 | |a Gemcitabine |2 nationallicence | |
| 690 | 7 | |a Docetaxel |2 nationallicence | |
| 700 | 1 | |a Yoneyama |D Takahiro |u Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Aomori, Japan |4 aut | |
| 700 | 1 | |a Imai |D Atsushi |u Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Aomori, Japan |4 aut | |
| 700 | 1 | |a Hatakeyama |D Shingo |u Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Aomori, Japan |4 aut | |
| 700 | 1 | |a Hashimoto |D Yasuhiro |u Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Aomori, Japan |4 aut | |
| 700 | 1 | |a Koie |D Takuya |u Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Aomori, Japan |4 aut | |
| 700 | 1 | |a Ohyama |D Chikara |u Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Aomori, Japan |4 aut | |
| 773 | 0 | |t International Journal of Clinical Oncology |d Springer Japan |g 20/6(2015-12-01), 1179-1184 |x 1341-9625 |q 20:6<1179 |1 2015 |2 20 |o 10147 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10147-015-0846-z |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10147-015-0846-z |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Yoneyama |D Takahiro |u Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Aomori, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Imai |D Atsushi |u Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Aomori, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Hatakeyama |D Shingo |u Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Aomori, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Hashimoto |D Yasuhiro |u Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Aomori, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Koie |D Takuya |u Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Aomori, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Ohyama |D Chikara |u Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Aomori, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t International Journal of Clinical Oncology |d Springer Japan |g 20/6(2015-12-01), 1179-1184 |x 1341-9625 |q 20:6<1179 |1 2015 |2 20 |o 10147 | ||